Autologous Blinatumomab-expanded T-Cells

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous, peripheral blood-derived polyclonal activated T-cells that have been expanded and activated ex-vivo using blinatumomab and recombinant human IL2 (rhIL-2) and depleted of contaminating CD19+ tumor cells, with potential immunomodulating activity. Upon administration, these blinatumomab-expanded T-cells (BET), composed of functional polyclonal CD4+ and CD8+ T-cells and mostly effector and central memory cells, may induce immunological recovery. BET cell expansion leads to the lysis and elimination of contaminating CD19+ tumor cells. The elimination of contaminating tumor cells is important in the treatment of non-Hodgkin CD20 + indolent lymphoma (iNHL) and chronic lymphatic leukemia (CLL).

**Synonyms:** - BET - Blinatumomab-cultured T cells - Blinatumomab-expanded Peripheral Blood-derived T Cells - Blinatumomab-expanded T Cells